Access to Therapies: Radicava (edaravone) Update

Updated March 10, 2021 Updated October 5, 2020 Updated May 28, 2020  Originally posted October 22, 2019 In October 2018, Health Canada approved Radicava (edaravone) for use in Canada. As edaravone continues to move through the drug access pathway to become available to Canadians, there will continue to be important updates for those in our […]

Radicava (edaravone): Take Action for Access

In October 2018, a new ALS treatment called Radicava was approved by Health Canada. It’s one of only two treatment options available to people living with this terminal disease. Today, over a year later, Radicava is still not available to Canadians through public drug plans. We want to change that. Join us in advocating for […]

Because Of You: ALS Canada’s 2018 Annual Report

Every day, more than 3,000 people and families throughout Ontario and Canada live with the realities of ALS, a devastating disease that takes away dreams, abilities, and lives. But for all ALS takes, it cannot take away our shared desire for a future without this disease. We rely on you – our generous donors – […]

Health Canada has approved Radicava (edaravone), a second ALS treatment for Canadians

Highlights: On October 4, Health Canada approved Radicava (edaravone) for the treatment of ALS. Health Canada’s terminology for this approval is called a Notice of Compliance, or NOC. The approval follows a 180-day priority review of the drug. Approval from Health Canada means that Radicava (edaravone) can be marketed and sold in Canada. Other considerations, […]

Radicava (edaravone): Make your voice heard

Updated July 18, 2018 The Canadian Agency for Drugs and Technologies in Health (CADTH) recently posted an open call for patient input on Radicava (edaravone). This is an additional step along the approval and affordability pathway for the drug, which is currently being reviewed by Health Canada. In response to CADTH’s call for patient input, […]

How new drugs become approved and available to Canadians

With the news that manufacturer MT Pharma is pursuing the regulatory channels necessary to bring the drug edaravone to Canada, the ALS community in this country finds itself facing the possibility of a second treatment option nearly 20 years after riluzole was approved. But how does any new drug become approved in Canada – and […]

A second ALS treatment, edaravone, has been newly approved in the United States

Updated October 5, 2017 Highlights: In May 2017 the United States Food and Drug Administration approved edaravone (also referred to as Radicava and Radicut) for the treatment of ALS. It’s the second ALS drug to be approved in the US. The first drug, riluzole, was approved more than 20 years ago. Radicava became available in […]